Alzheimer's disease is the most prevalent form of dementia. However, diagnostic tools and pathology biomarkers are still scarce. The activity of beta-secretase 1 in cerebrospinal fluid has been investigated as a potential biomarker for mild cognitive impairment and Alzheimer's disease. But the methodology to extract cerebrospinal fluid is invasive. In this study, patients with mild cognitive impairment and patients with probable Alzheimer's disease were recruited to measure plasma beta-secretase 1 activity matched to cognitive follow-up during 3 years. The results show that beta-secretase 1 activity is significantly increased in demented patients compared to controls and in those evolving from mild cognitive impairment to probable Alzheimer's disease compared to cognitively stable patients. Thus, it seems that plasma beta-secretase 1 activity can be a biomarker for Alzheimer's disease but also can predict the transition from mild cognitive impairment to probable Alzheimer's disease.
Increased plasma Beta-Secretase 1 may predict conversion to Alzheimer’s disease dementia in individuals with mild cognitive impairment
The IE from MS no longer understands current scripting languages, the latest main version (version 11) is from 2013 and has not been further developed since 2015.
Our recommendation: Use only the latest versions of modern browsers, for example Google Chrome, Mozilla Firefox or Microsofrt Edge, because only this guarantees you sufficient protection against infections and the correct display of websites!